Chemical formula: C₂₇H₃₄N₄O Molecular mass: 430.585 g/mol PubChem compound: 9331
There is no data from the use of piritramide in pregnant women and only insufficient experimental studies in animals. The potential risk to humans is unknown. Piritramide is therefore not recommended during pregnancy unless clearly necessary.
It is not known whether piritramide passes into breast milk. However, it is known that other opioids pass into breast milk. Piritramide should not be used whilst breast-feeding unless absolutely necessary. Breast-feeding should be discontinued during treatment with piritramide and only resume at least 24 hours after the last dose of piritramide.
It cannot be ruled out that chronic use during pregnancy may lead to habituation and to post-partum withdrawal symptoms in the neonate.
Although it varies widely between individuals, the sedative effect of piritramide must be borne in mind. As a precaution the patient should wait for a minimum of 6 to 8 hours after a single dose of 20 mg piritramide and for a minimum of 12 to 24 hours after repeated administration.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
